Iovance Signs a License Agreement with Novartis to Develop and Commercialize IOV-3001

 Iovance Signs a License Agreement with Novartis to Develop and Commercialize IOV-3001

Iovance Signs a License Agreement with Novartis to Develop & Commercialize IOV-3001

Shots:

  • Novartis to receive up front, milestones on the initiation of dosing in different phases of clinical development and approval of the IOV-3001 in the US, EU, and Japan along with royalties on sales of the product
  • Iovance to get right to develop & commercialize Novartis’ IOV-3001 and will focus on GMP manufacturing of IOV-3001 during 2020 with the expected initiation of IND-enabling activities in 2021
  • IOV-3001 is an engineered IL-2 CDR graft targeting IL2R beta-gamma-expressing cells & limiting IL2R alpha-beta-gamma-dependent Treg activation with an improved half-life and better safety profile than other IL-2 inhibitors

Click here to­ read full press release/ article | Ref: Iovance Biotherapeutics | Image:  Iovance Biotherapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post